Researchers at Vanderbilt University have discovered promising drug targets for previously hard-to-treat kinds of melanoma, suggesting that some cancers believed not to have such targets actually do.
After continuing to lose money in its fiscal 2013 third quarter, Trovagene insists it is poised to start generating revenue and results through new licensing, R&D partnerships and the launch of a precedent-setting urine-based cancer mutation-monitoring test.
For the third time this fall, Myriad Genetics is rolling out a new diagnostic product. This time, it's a melanoma skin biopsy test debuting first with a phased U.S. rollout and then in "key European markets" beginning in early 2014.
Scientists have found a new biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF, a discovery that could help better tailor treatment therapies for patients with these cancers.
In preclinical studies, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, called LEE011, showed upbeat results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies.
When it launched in March 2011, Yervoy became the only drug ever to extend survival in patients with advanced forms of melanoma. Now, new data show just how long the breakthrough drug can extend that survival: A few patients using Yervoy could tack on as much as a decade to their lives, according to a long-term study. And more than a few could see a few extra years.
A new study by researchers at the Moffitt Cancer Center in Tampa, FL, provides promising evidence that an injectable solution called PV-10 could be a potential new treatment for battling melanoma, the deadliest form of skin cancer.
When Mela Sciences won FDA approval for its cancer-identifying device back in 2011, the company hailed its technology as a huge advance in melanoma detection. But now, as MelaFind makes its way into U.S. hospitals, some physicians are concerned the device offers no benefit over low-tech tradition.
Two of GlaxoSmithKline's hopes for 2013 are now fulfilled: The company won FDA approval for its melanoma treatments Tafinlar and Mekinist, both targeted at patients with patients with certain genetic mutations. Together, the two oral drugs may top $600 million in sales by 2016, analysts say.
French diagnostics developer bioMérieux hitched up with GlaxoSmithKline to develop companion diagnostics for a pair of the drugmaker's melanoma treatments, and now the duo has something to celebrate as the FDA approved all three.